International Assets Investment Management LLC Decreases Position in Stryker Co. (NYSE:SYK)

International Assets Investment Management LLC decreased its position in shares of Stryker Co. (NYSE:SYK) by 99.7% during the fourth quarter, HoldingsChannel reports. The institutional investor owned 2,583 shares of the medical technology company’s stock after selling 851,186 shares during the period. International Assets Investment Management LLC’s holdings in Stryker were worth $927,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Dunhill Financial LLC increased its holdings in shares of Stryker by 94.9% in the 3rd quarter. Dunhill Financial LLC now owns 76 shares of the medical technology company’s stock worth $27,000 after purchasing an additional 37 shares in the last quarter. Centennial Bank AR increased its holdings in Stryker by 106.7% in the 2nd quarter. Centennial Bank AR now owns 93 shares of the medical technology company’s stock worth $32,000 after buying an additional 48 shares in the last quarter. Darwin Wealth Management LLC bought a new stake in Stryker in the 3rd quarter worth about $36,000. HBW Advisory Services LLC bought a new position in Stryker during the 3rd quarter valued at about $42,000. Finally, Hara Capital LLC bought a new stake in shares of Stryker in the third quarter worth approximately $42,000. Institutional investors own 77.09% of the company’s stock.

Insider Activity

In other news, CEO Kevin Lobo sold 57,313 shares of the company’s stock in a transaction dated Thursday, November 7th. The shares were sold at an average price of $368.70, for a total transaction of $21,131,303.10. Following the sale, the chief executive officer now directly owns 100,027 shares in the company, valued at approximately $36,879,954.90. This represents a 36.43 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 5.50% of the company’s stock.

Stryker Price Performance

SYK stock opened at $364.19 on Friday. The company has a market capitalization of $138.84 billion, a PE ratio of 39.03, a price-to-earnings-growth ratio of 2.82 and a beta of 0.95. The company’s fifty day moving average price is $375.42 and its 200-day moving average price is $357.51. Stryker Co. has a one year low of $298.52 and a one year high of $398.20. The company has a debt-to-equity ratio of 0.66, a quick ratio of 1.22 and a current ratio of 1.91.

Stryker (NYSE:SYK) last released its quarterly earnings data on Tuesday, October 29th. The medical technology company reported $2.87 EPS for the quarter, beating the consensus estimate of $2.77 by $0.10. Stryker had a net margin of 16.34% and a return on equity of 23.07%. The business had revenue of $5.49 billion during the quarter, compared to the consensus estimate of $5.37 billion. During the same quarter in the prior year, the firm earned $2.46 EPS. The business’s revenue was up 11.9% on a year-over-year basis. On average, equities analysts anticipate that Stryker Co. will post 12.06 EPS for the current fiscal year.

Stryker Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, January 31st. Shareholders of record on Tuesday, December 31st will be paid a $0.84 dividend. This is an increase from Stryker’s previous quarterly dividend of $0.80. The ex-dividend date is Tuesday, December 31st. This represents a $3.36 dividend on an annualized basis and a yield of 0.92%. Stryker’s payout ratio is presently 36.01%.

Analyst Upgrades and Downgrades

Several research firms have recently weighed in on SYK. UBS Group increased their price target on Stryker from $366.00 to $370.00 and gave the company a “neutral” rating in a report on Wednesday, October 30th. Citigroup upped their price target on shares of Stryker from $411.00 to $450.00 and gave the company a “buy” rating in a research report on Wednesday, December 11th. Canaccord Genuity Group boosted their target price on shares of Stryker from $360.00 to $400.00 and gave the company a “buy” rating in a research report on Wednesday, October 30th. JMP Securities reiterated a “market perform” rating on shares of Stryker in a research report on Tuesday. Finally, JPMorgan Chase & Co. boosted their price objective on shares of Stryker from $375.00 to $420.00 and gave the company an “overweight” rating in a research report on Wednesday, October 30th. Four equities research analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. Based on data from MarketBeat.com, Stryker has a consensus rating of “Moderate Buy” and an average price target of $405.80.

Stryker Profile

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in total joint replacements, such as hip, knee and shoulder, and trauma and extremities surgeries.